

**Generic Name:** Bempedoic acid

**Preferred:** N/A

**Therapeutic Class or Brand Name:** Nexletol®

**Non-preferred:** N/A

**Applicable Drugs (if Therapeutic Class):** Lipid Lowering Agent

**Date of Origin:** 3/23/2020

**GPI Code:** 39380020000320

**Date Last Reviewed / Revised:** N/A

## PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I - III are met)

- I. Documented diagnosis of one of the following conditions A Or B AND must meet criteria listed under applicable diagnosis:
  - A. Heterozygous familial hypercholesterolemia (HeFH) and following criterion and conditions are met:
    1. Diagnosed with genetic typing OR measured LDL-C  $\geq$  190 mg/dL prior to treatment with a statin and the following criteria are met:
    2. Minimum age requirement: 18 years old.
  - B. Clinical atherosclerotic cardiovascular disease (ASCVD) and criterion 1 is met:
    1. Minimum age requirement: 18 years old.
- II. Documentation that patient meets the following criteria A and B
  - A. Treatment with maximally tolerated statin and ezetimibe daily for  $\geq$ 24 weeks and
  - B. LDL-C remains  $\geq$ 100 mg/dL or a 50% reduction in LDL-c has not been achieved.
- III. Documentation Prescriber must be a doctor of internal medicine, cardiologist, or endocrinologist.

## EXCLUSION CRITERIA

- Concurrent use with simvastatin > 20mg or pravastatin > 40mg
- Documented history of tendon rupture or tendon disorders.
- Documented history of chronic liver disease or abnormal liver enzymes.

## OTHER CRITERIA

- N/A

## QUANTITY / DAYS SUPPLY RESTRICTIONS

- Quantifies up to 30 tablets for 30 days.

## APPROVAL LENGTH

- **Authorization:** 6 months
- **Re-Authorization:** An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective.

## APPENDIX

N/A

## REFERENCES

1. Goldberg AC, Leiter LA, Stroes ES, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. *JAMA* 2019;322:1780-8.
2. Bempedoic acid (Nexletol®) [package insert]. Ann Arbor, MI; Esperion Therapeutics, Inc.
3. Medi-Span.
4. Up To Date

**DISCLAIMER:** Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.